Literature DB >> 22187162

A case of steroid-resistant nephrotic syndrome associated with systemic lupus erythematosus.

I Ito1, M Nishida2, S Morioka1, T Nozaki1, T Imamura1, A Morimoto1, S Akioka1, T Sugimoto1, K Hamaoka3, H Hosoi1.   

Abstract

We report on an 11-year-old girl who developed steroid-resistant nephrotic syndrome (NS) at the onset of systemic lupus erythematosus (SLE), and clinical and renal histological findings suggested that her NS would be associated with SLE-related podocytopathy. Although initial treatment with intravenous pulse methylprednisolone was ineffective, following treatment with cyclosporine and an angiotensin receptor blocker was effective for her nephrotic proteinuria. She had developed posterior reversible encephalopathy syndrome (PRES), and mycophenolate mofetil (MMF) was started instead of cyclosporine. At present, 45 months after the onset, she is in remission of both NS and SLE. This case indicates that NS associated with SLE-related podocytopathy should be included in the spectrum of glomerulopathy accompanying SLE, also in the pediatric population.
© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  idiopathic nephrotic syndrome; podocytopathy; systemic lupus erythematosus

Mesh:

Substances:

Year:  2011        PMID: 22187162     DOI: 10.1177/0961203311432740

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Lupus podocytopathy superimposed on diabetic glomerulosclerosis: A case report.

Authors:  Lin Liu; Brian Murray; John E Tomaszewski
Journal:  Medicine (Baltimore)       Date:  2021-09-17       Impact factor: 1.889

2.  Lupus podocytopathy and antiphospholipid syndrome in a child with SLE: A case report and literature review.

Authors:  Guo-Min Li; Yi-Fan Li; Qiao-Qian Zeng; Xiao-Mei Zhang; Hai-Mei Liu; Jia-Yan Feng; Yu Shi; Bing-Bing Wu; Hong Xu; Li Sun
Journal:  Front Pediatr       Date:  2022-08-19       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.